Percentage of patients undergoing carotid endarterectomy (CEA) who are taking an anti-platelet agent (aspirin or clopidogrel or equivilant such as aggrenox/tiglacor etc) within 48 hours prior to surgery and are prescribed this medication at hospital discharge following surgery
- Measure TypeElectronic Clinical Quality Measure (eCQM)Level Of AnalysisCare SettingNumerator
Patients over age 18 undergoing carotid endarterectomy who received anti-platlet agents such as aspirin or aspirin-like agents, or P2y12 antagonists within 48 hours prior to the initiation of surgery AND are prescribed this medication at hospital discharge following surgery.
DenominatorPatients over age 18 undergoing carotid endarterectomy.
ExclusionsPatients with known intolerance to anti-platlet agents such as aspirin or aspirin-like agents, or P2y12 antagonists, or those on heparin or other intravenous anti-coagulants; patients with active bleeding or undergoing urgent or emergent operations or endarterectomy combined with cardiac surgery. Patients with known intolerance to anti-platlet agents such as aspirin or aspirin-like agents, or P2y12 antagonists, or those on or other intravenous anti-coagulants; patients with active bleeding or undergoing urgent or emergent operations or endarterectomy combined with cardiac surgery.
Testing Data Sources
- Measure StructureClinical Condition Topic AreaNon Condition SpecificTarget PopulationMeasure Selection AttributesNational Quality Strategy PrioritiesEffective Communication and Care Coordination
- Risk Adjustment
- Most Recent Endorsement ActivityEndorsed Surgery Endorsement Maintenance Project 2014Initial EndorsementNext Planned Maintenance ReviewSurgery Spring 2024Endorsement StatusLast Updated
- StewardSteward Organization Email